Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) ...
Jun 3, 2022
0
35
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people ...
May 25, 2022
0
6
A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma ...
May 12, 2022
0
18
Joyce Ares had just turned 74 and was feeling fine when she agreed to give a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer.
Apr 11, 2022
0
4
Roughly 620,000 new cases of lymphoma were diagnosed worldwide, according to the World Cancer Research Fund International's 2020 report. Survival rates have improved as advances develop in treatment, such as chimeric antigen ...
Apr 5, 2022
0
11
Japanese collaborative research teams have discovered new mechanisms of action by extracellular vesicles (EV) for the development and malignant progression of lymphomas.
Mar 28, 2022
0
54
(HealthDay)—Night shift work may increase the risk for chronic lymphocytic leukemia (CLL), according to a study published online Jan. 13 in Occupational & Environmental Medicine.
Jan 25, 2022
0
0
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study ...
Jan 3, 2022
0
84
(HealthDay)—For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) leads to improvements in event-free survival and response compared with standard care, according to a study published ...
Dec 21, 2021
0
37
A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin ...
Dec 14, 2021
0
25
